What is the recommended dosing for Metanx (L‑methylfolate, pyridoxal‑5′‑phosphate, methylcobalamin)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Dosing of Metanx

The recommended dosing for Metanx is one capsule twice daily (or two capsules once daily), with each capsule containing 3 mg L-methylfolate calcium, 35 mg pyridoxal-5'-phosphate, and 2 mg methylcobalamin.

Standard Dosing Regimen

The typical prescription for Metanx follows a straightforward protocol:

  • Standard dose: 1 capsule twice daily (morning and evening)
  • Alternative: 2 capsules once daily
  • Each capsule contains:
    • L-methylfolate calcium: 3 mg
    • Pyridoxal-5'-phosphate (P5P): 35 mg
    • Methylcobalamin: 2 mg

This dosing has been validated in clinical trials for diabetic peripheral neuropathy and other conditions requiring active B-vitamin supplementation 1, 2.

Clinical Evidence for This Dose

The twice-daily dosing (total daily dose: 6 mg L-methylfolate, 70 mg P5P, 4 mg methylcobalamin) demonstrated significant clinical benefits in randomized controlled trials. In a 24-week study of 214 patients with diabetic neuropathy, this regimen showed clinically significant improvement in neuropathy symptom scores by week 16 and week 24, along with meaningful reductions in homocysteine levels 2.

A separate study using the same dosing showed restoration of cutaneous sensation in diabetic peripheral neuropathy, with the greatest improvement occurring between baseline and one year of treatment 1.

Duration and Timing Considerations

  • Onset of effect: Symptomatic improvement typically begins around 16 weeks, though some patients may notice benefits earlier 2
  • Maximum benefit: Often achieved by 6-12 months of continuous therapy 1
  • Administration: Can be taken with or without food; no specific timing restrictions mentioned in clinical trials

Important Clinical Caveats

Do not confuse Metanx with other products: The FDA drug label evidence 3 appears to reference a homeopathic product called "MET TOX" with completely different dosing (6 drops orally 4 times daily). This is NOT the same as Metanx prescription medical food. Metanx is a prescription medical food containing specific active forms of B vitamins, not a homeopathic preparation.

Safety profile: The clinical trials showed adverse events were infrequent, with no single event occurring in ≥2% of subjects 2. This formulation uses the active, bioavailable forms of B vitamins that bypass common metabolic bottlenecks, particularly important for patients with MTHFR polymorphisms.

Special populations: While the evidence focuses on diabetic neuropathy, recent studies suggest potential benefits in patients with MTHFR polymorphisms for cardiovascular risk reduction (homozygous carriers showed 48.3% reduction in homocysteine with similar dosing) 4 and depression management (15 mg/day L-methylfolate as adjunctive therapy) 5.

Monitoring

No specific laboratory monitoring is required for Metanx itself, though tracking clinical response through symptom scores and, when relevant, homocysteine levels can help assess treatment efficacy. The formulation's safety profile does not necessitate routine blood work specifically for the supplement, unlike methotrexate or other medications that may deplete these vitamins 6, 7, 8.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.